Atossa Genetics (NASDAQ:ATOS) Releases Earnings Results, Misses Estimates By $0.12 EPS

Atossa Genetics (NASDAQ:ATOS) posted its earnings results on Friday. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12), FiscalAI reports.

Atossa Genetics Trading Down 1.2%

Shares of Atossa Genetics stock opened at $5.60 on Friday. The business’s fifty day simple moving average is $5.18 and its 200 day simple moving average is $8.28. The firm has a market capitalization of $48.22 million, a P/E ratio of -1.56 and a beta of 1.25. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ATOS. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a report on Monday, April 20th. Ascendiant Capital Markets dropped their target price on Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. Finally, HC Wainwright raised their target price on Atossa Genetics to $25.00 and gave the company a “buy” rating in a report on Thursday, March 26th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $36.33.

Institutional Trading of Atossa Genetics

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Atossa Genetics by 4.2% during the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after acquiring an additional 245,717 shares during the period. Ameriprise Financial Inc. bought a new stake in Atossa Genetics during the second quarter worth $2,468,000. Renaissance Technologies LLC lifted its holdings in Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares during the period. Geode Capital Management LLC lifted its holdings in Atossa Genetics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after acquiring an additional 9,627 shares during the period. Finally, State Street Corp lifted its holdings in Atossa Genetics by 31.2% during the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after acquiring an additional 141,990 shares during the period. 12.74% of the stock is currently owned by institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.